Agenus Inc (AGEN)
13.07
+0.55
(+4.39%)
USD |
NASDAQ |
May 03, 16:00
13.05
-0.02
(-0.15%)
After-Hours: 20:00
Agenus Revenue (Quarterly): 83.80M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 83.80M |
| September 30, 2023 | 24.31M |
| June 30, 2023 | 25.30M |
| March 31, 2023 | 22.90M |
| December 31, 2022 | 28.39M |
| September 30, 2022 | 22.77M |
| June 30, 2022 | 20.93M |
| March 31, 2022 | 25.94M |
| December 31, 2021 | 20.26M |
| September 30, 2021 | 252.95M |
| June 30, 2021 | 10.73M |
| March 31, 2021 | 11.72M |
| December 31, 2020 | 31.26M |
| September 30, 2020 | 14.83M |
| June 30, 2020 | 26.94M |
| March 31, 2020 | 15.13M |
| December 31, 2019 | 34.50M |
| September 30, 2019 | 19.94M |
| June 30, 2019 | 15.72M |
| March 31, 2019 | 79.89M |
| December 31, 2018 | 6.451M |
| September 30, 2018 | 12.80M |
| June 30, 2018 | 15.90M |
| March 31, 2018 | 1.636M |
| December 31, 2017 | 8.354M |
| Date | Value |
|---|---|
| September 30, 2017 | 3.359M |
| June 30, 2017 | 4.208M |
| March 31, 2017 | 26.96M |
| December 31, 2016 | 5.576M |
| September 30, 2016 | 4.446M |
| June 30, 2016 | 6.592M |
| March 31, 2016 | 5.959M |
| December 31, 2015 | 7.639M |
| September 30, 2015 | 6.848M |
| June 30, 2015 | 6.377M |
| March 31, 2015 | 3.953M |
| December 31, 2014 | 1.619M |
| September 30, 2014 | 1.563M |
| June 30, 2014 | 3.074M |
| March 31, 2014 | 0.7209M |
| December 31, 2013 | 0.3926M |
| September 30, 2013 | 0.736M |
| June 30, 2013 | 0.8074M |
| March 31, 2013 | 1.109M |
| December 31, 2012 | 1.090M |
| September 30, 2012 | 0.8688M |
| June 30, 2012 | 0.6268M |
| March 31, 2012 | 13.37M |
| December 31, 2011 | 0.6438M |
| September 30, 2011 | 0.6537M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
10.73M
Minimum
Jun 2021
252.95M
Maximum
Sep 2021
37.28M
Average
22.90M
Median
Mar 2023
Revenue (Quarterly) Benchmarks
| Protalix BioTherapeutics Inc | 10.49M |
| InfuSystems Holdings Inc | 31.77M |
| PAVmed Inc | 1.049M |
| Allogene Therapeutics Inc | -0.044M |
| Pfizer Inc | 14.88B |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -46.29M |
| Total Expenses (Quarterly) | 88.16M |
| EPS Diluted (Quarterly) | -2.40 |
| Enterprise Value | 222.52M |
| Gross Profit Margin (Quarterly) | 20.07% |
| Profit Margin (Quarterly) | -55.24% |
| Earnings Yield | -107.1% |
| Normalized Earnings Yield | -107.37 |